| Year |
Citation |
Score |
| 2024 |
Eastwood SM, Meyer MR, Kirmess KM, Wente-Roth TL, Irvin F, Holubasch MS, Verghese PB, West T, Braunstein JB, Yarasheski KE, Contois JH. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics (Basel, Switzerland). 14. PMID 39202226 DOI: 10.3390/diagnostics14161739 |
0.74 |
|
| 2024 |
Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvadó G, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. Jama. PMID 39068545 DOI: 10.1001/jama.2024.13855 |
0.701 |
|
| 2024 |
Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas RG, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease. Alzheimer's Research & Therapy. 16: 151. PMID 38970127 DOI: 10.1186/s13195-024-01490-z |
0.528 |
|
| 2024 |
Molina-Henry DP, Raman R, Liu A, Langford O, Johnson K, Shum LK, Glover CM, Dhadda S, Irizarry M, Jimenez-Maggiora G, Braunstein JB, Yarasheski K, Venkatesh V, West T, Verghese PB, et al. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38629508 DOI: 10.1002/alz.13803 |
0.729 |
|
| 2024 |
Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas R, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease. Medrxiv : the Preprint Server For Health Sciences. PMID 38562783 DOI: 10.1101/2024.03.20.24304638 |
0.53 |
|
| 2024 |
Meyer MR, Kirmess KM, Eastwood S, Wente-Roth TL, Irvin F, Holubasch MS, Venkatesh V, Fogelman I, Monane M, Hanna L, Rabinovici GD, Siegel BA, Whitmer RA, Apgar C, Bateman RJ, ... ... West T, et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38491912 DOI: 10.1002/alz.13764 |
0.782 |
|
| 2023 |
Cook JD, Malik A, Plante DT, Norton D, Koscik RL, Du L, Bendlin BB, Kirmess KM, Holubasch MS, Meyer MR, Venkatesh V, West T, Verghese PB, Yarasheski KE, Thomas KV, et al. Associations of Sleep Duration and Daytime Sleepiness with Plasma Amyloid Beta and Cognitive Performance in Cognitively Unimpaired, Middle-Aged and Older Adult African Americans. Sleep. PMID 38011629 DOI: 10.1093/sleep/zsad302 |
0.654 |
|
| 2023 |
Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, Wente-Roth T, Kirmess KM, Ngolab J, Winston CN, Jimenez-Maggiora G, Rafii MS, Sachdev P, West T, Yarasheski KE, et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37932961 DOI: 10.1002/alz.13542 |
0.422 |
|
| 2023 |
Fischer B, Van Hulle CA, Langhough R, Norton D, Zuelsdorff M, Gooding DC, Wyman MF, Johnson A, Lambrou N, James T, Bouges S, Carter FP, Salazar H, Kirmess K, Holubasch M, ... ... West T, et al. Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AA-FAIM cohort. Alzheimer's & Dementia (New York, N. Y.). 9: e12414. PMID 37752907 DOI: 10.1002/trc2.12414 |
0.712 |
|
| 2023 |
Monane M, Johnson KG, Snider BJ, Turner RS, Drake JD, Maraganore DM, Bicksel JL, Jacobs DH, Ortega JL, Henderson J, Jiang Y, Huang S, Coppinger J, Fogelman I, West T, et al. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Annals of Clinical and Translational Neurology. PMID 37550958 DOI: 10.1002/acn3.51863 |
0.351 |
|
| 2023 |
Fogelman I, West T, Braunstein JB, Verghese PB, Kirmess KM, Meyer MR, Contois JH, Shobin E, Ferber KL, Gagnon J, Rubel CE, Graham D, Bateman RJ, Holtzman DM, Huang S, et al. Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. Annals of Clinical and Translational Neurology. PMID 36975407 DOI: 10.1002/acn3.51763 |
0.793 |
|
| 2023 |
Wisch JK, Gordon BA, Boerwinkle AH, Luckett PH, Bollinger JG, Ovod V, Li Y, Henson RL, West T, Meyer MR, Kirmess KM, Benzinger TLS, Fagan AM, Morris JC, Bateman RJ, et al. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40. Alzheimer's & Dementia (Amsterdam, Netherlands). 15: e12405. PMID 36874595 DOI: 10.1002/dad2.12405 |
0.579 |
|
| 2023 |
Winston CN, Langford O, Levin N, Raman R, Yarasheski K, West T, Abdel-Latif S, Donohue M, Nakamura A, Toba K, Masters CL, Doecke J, Sperling RA, Aisen PS, Rissman RA. Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 36710683 DOI: 10.3233/JAD-221118 |
0.332 |
|
| 2022 |
Aschenbrenner AJ, Li Y, Henson RL, Volluz K, Hassenstab J, Verghese P, West T, Meyer MR, Kirmess KM, Fagan AM, Xiong C, Holtzman D, Morris JC, Bateman RJ, Schindler SE. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Annals of Clinical and Translational Neurology. PMID 36183195 DOI: 10.1002/acn3.51670 |
0.762 |
|
| 2022 |
Hartz SM, Mozersky J, Schindler SE, Linnenbringer E, Wang J, Gordon BA, Raji CA, Moulder KL, West T, Benzinger TLS, Cruchaga C, Hassenstab JJ, Bierut LJ, Xiong C, Morris JC. A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36178120 DOI: 10.1002/alz.12781 |
0.323 |
|
| 2022 |
Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, et al. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Neurology. PMID 35450967 DOI: 10.1212/WNL.0000000000200358 |
0.581 |
|
| 2022 |
Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, Whitmer RA, Apgar C, Hanna L, Kanekiyo M, Kaplow J, Koyama A, Verbel D, Holubasch MS, Knapik SS, ... ... West T, et al. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. Jama Network Open. 5: e228392. PMID 35446396 DOI: 10.1001/jamanetworkopen.2022.8392 |
0.781 |
|
| 2021 |
Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Jackson EN, Harpstrite SE, Verghese PB, West T, Fogelman I, Braunstein JB, Yarasheski KE, Contois JH. The PrecivityAD™ Test: Accurate and Reliable LC-MS/MS Assays for Quantifying Plasma Amyloid Beta 40 and 42 and Apolipoprotein E Proteotype for the Assessment of Brain Amyloidosis. Clinica Chimica Acta; International Journal of Clinical Chemistry. PMID 34015303 DOI: 10.1016/j.cca.2021.05.011 |
0.733 |
|
| 2021 |
West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Molecular Neurodegeneration. 16: 30. PMID 33933117 DOI: 10.1186/s13024-021-00451-6 |
0.79 |
|
| 2019 |
Paterson RW, Gabelle A, Lucey BP, Barthélemy NR, Leckey CA, Hirtz C, Lehmann S, Sato C, Patterson BW, West T, Yarasheski K, Rohrer JD, Wildburger NC, Schott JM, Karch CM, et al. SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews. Neurology. PMID 31222062 DOI: 10.1038/S41582-019-0222-0 |
0.576 |
|
| 2019 |
Yarasheski KE, West T, Verghese PB, Hu Y, Kirmess K, Meyer M, Smith E, Harpstrite S, Holubasch M, Knapik S, Harlan A, Fogelman I, Braunstein JB. F4-01-01: PLASMA TEST FOR AMYLOID RISK SCREENING: THE C2
N SPONSORED PARIS ADD-ON STUDY TO IDEAS. Alzheimer's & Dementia. 15: P1216-P1216. DOI: 10.1016/J.Jalz.2019.06.4713 |
0.673 |
|
| 2017 |
Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine. 9. PMID 28424326 DOI: 10.1126/Scitranslmed.Aal2029 |
0.735 |
|
| 2017 |
Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, Buono C, Zhou W, DeCristofaro M, Douville J, Goodrich GG, Mansfield K, Saravanan C, Cumin F, Webb RL, et al. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey. Toxicology and Applied Pharmacology. PMID 28315356 DOI: 10.1016/J.Taap.2017.03.014 |
0.763 |
|
| 2017 |
Budur K, West T, Braunstein JB, Fogelman I, Bordelon YM, Litvan I, Roberson ED, Hu H, Verghese PB, Bateman RJ, Florian H, Wang D, Ryman D, Gault L, Goss S, et al. [O2-17-01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P599-P600. DOI: 10.1016/J.Jalz.2017.07.241 |
0.696 |
|
| 2016 |
Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. Alzheimer's & Dementia (New York, N. Y.). 2: 110-120. PMID 29067298 DOI: 10.1016/J.Trci.2016.06.001 |
0.751 |
|
| 2016 |
Ghosal K, Haag M, Verghese PB, West T, Veenstra T, Braunstein JB, Bateman RJ, Holtzman DM, Landreth GE. A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2: 110-120. DOI: 10.1016/j.trci.2016.06.001 |
0.764 |
|
| 2014 |
Sheline YI, West T, Yarasheski K, Jasielec MS, Hettinger JC, Tripoli DL, Xiong C, Frederiksen C, Grzelak MV, Bateman RJ, Morris JC, Lee JM, Cirrito JR. Reply to comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice". Science Translational Medicine. 6: 268lr4. PMID 25540323 DOI: 10.1126/Scitranslmed.3010609 |
0.71 |
|
| 2014 |
Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, Mintun MA, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Science Translational Medicine. 6: 236re4. PMID 24828079 DOI: 10.1126/Scitranslmed.3008169 |
0.749 |
|
| 2014 |
Cirrito J, Sheline Y, Fisher J, Lee J, West T. O2-04-04: SPECIFIC SEROTONIN RECEPTOR SUBTYPES RESPONSIBLE FOR DECREASED CSF AB PRODUCTION Alzheimer's & Dementia. 10: P171-P171. DOI: 10.1016/J.Jalz.2014.04.176 |
0.561 |
|
| 2013 |
Sheline Y, West T, Yarasheski K, Regina K, Swarm R, Kharasch E, Cirrito J, Frederiksen C, Chott R. P4-067: Citalopram decreases acute CSF beta-amyloid concentration in young, healthy study participants Alzheimer's & Dementia. 9: P728-P729. DOI: 10.1016/J.Jalz.2013.05.1456 |
0.616 |
|
| 2012 |
Xiao Q, Ford AL, Xu J, Yan P, Lee KY, Gonzales E, West T, Holtzman DM, Lee JM. Bcl-x pre-mRNA splicing regulates brain injury after neonatal hypoxia-ischemia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 13587-96. PMID 23015448 DOI: 10.1523/Jneurosci.2617-12.2012 |
0.385 |
|
| 2012 |
Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proceedings of the National Academy of Sciences of the United States of America. 109: 15502-7. PMID 22927427 DOI: 10.1073/Pnas.1206446109 |
0.775 |
|
| 2012 |
Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, Seredenina T, Arbez N, Zhu S, Sommers K, Qian J, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nature Medicine. 18: 153-8. PMID 22179319 DOI: 10.1038/Nm.2558 |
0.482 |
|
| 2011 |
Lodygensky GA, West T, Moravec MD, Back SA, Dikranian K, Holtzman DM, Neil JJ. Diffusion characteristics associated with neuronal injury and glial activation following hypoxia-ischemia in the immature brain. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 66: 839-45. PMID 21394776 DOI: 10.1002/Mrm.22869 |
0.428 |
|
| 2010 |
Satoh A, Brace CS, Ben-Josef G, West T, Wozniak DF, Holtzman DM, Herzog ED, Imai S. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 10220-32. PMID 20668205 DOI: 10.1523/Jneurosci.1385-10.2010 |
0.418 |
|
| 2010 |
Lodygensky GA, West T, Stump M, Holtzman DM, Inder TE, Neil JJ. In vivo MRI analysis of an inflammatory injury in the developing brain. Brain, Behavior, and Immunity. 24: 759-67. PMID 19945527 DOI: 10.1016/J.Bbi.2009.11.005 |
0.425 |
|
| 2009 |
West T, Stump M, Lodygensky G, Neil JJ, Deshmukh M, Holtzman DM. Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal brain injury. Asn Neuro. 1. PMID 19570023 DOI: 10.1042/An20090005 |
0.367 |
|
| 2008 |
Wendland MF, Faustino J, West T, Manabat C, Holtzman DM, Vexler ZS. Early diffusion-weighted MRI as a predictor of caspase-3 activation after hypoxic-ischemic insult in neonatal rodents. Stroke; a Journal of Cerebral Circulation. 39: 1862-8. PMID 18420950 DOI: 10.1161/Strokeaha.107.506352 |
0.404 |
|
| 2007 |
West T, Atzeva M, Holtzman DM. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. Developmental Neuroscience. 29: 363-72. PMID 17762204 DOI: 10.1159/000105477 |
0.419 |
|
| 2006 |
Schlief ML, West T, Craig AM, Holtzman DM, Gitlin JD. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proceedings of the National Academy of Sciences of the United States of America. 103: 14919-24. PMID 17003121 DOI: 10.1073/Pnas.0605390103 |
0.407 |
|
| 2006 |
West T, Atzeva M, Holtzman DM. Caspase-3 deficiency during development increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways. Neurobiology of Disease. 22: 523-37. PMID 16480886 DOI: 10.1016/J.Nbd.2005.12.017 |
0.429 |
|
| 2005 |
Young C, Roth KA, Klocke BJ, West T, Holtzman DM, Labruyere J, Qin YQ, Dikranian K, Olney JW. Role of caspase-3 in ethanol-induced developmental neurodegeneration. Neurobiology of Disease. 20: 608-14. PMID 15927478 DOI: 10.1016/J.Nbd.2005.04.014 |
0.416 |
|
| 2005 |
Maas JW, Indacochea RA, Muglia LM, Tran TT, Vogt SK, West T, Benz A, Shute AA, Holtzman DM, Mennerick S, Olney JW, Muglia LJ. Calcium-stimulated adenylyl cyclases modulate ethanol-induced neurodegeneration in the neonatal brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2376-85. PMID 15745964 DOI: 10.1523/Jneurosci.4940-04.2005 |
0.441 |
|
| Show low-probability matches. |